3-11-80 Vol. 45 No. 40 Pageo 16303-15918




Tuesday March 11, 1980

## CORRECTION TO

Federal Register, Thursday, November 29, 1979, Part III, Appendix C; Analysis of Trihalomethanes in Drinking Water



- 15503 Cancer Control Month Presidential proclamation
- 15677 Desegregation HEW/NIE announces a program of research grants; closing dates: 5-22 (small grants) and 10-7-80 (major grants)
- 15547, Hazardous waste: Dioxin EPA promotts the disposal of Tetrachlorodibenzo-P-Dioxin; comments by 5-12-80, hearing on 5-28-80 (2 documents)
- 15884 Food Stamps USDA/FNS issues requirements for establishing Performance Reporting System; effective 4-10-80 (Part V of this issue)
- 15:050 Medicare HEW/HCFA issues notice regarding reimbursement of hospital-based physicians; effective 7-1-80
- 15566 Supplemental Security Income HEW/SSA proposes rule defining who qualifies as a spouse, child, or parent; comments by 5-12-80
- 15673 Radiological Health HEW/FDA announces availability of preamble compilation for published documents
- 15802 Grain USDA/FGIS publishes standards; effective 4-10-80 (Part II of this issue)





## 40 CFR Part 141

[FRL 1431-1]

National Interim Primary Drinking Water Regulations; Control of Trihalomethanes in Drinking Water; Correction

AGENCY: Environmental Protection Agency (EPA). ACTION: Final Rule; Correction.

SUMMARY: This document corrects errors found in Federal Register Doc. 79–36442, appearing at page 68624 in the Federal Register of November 29, 1979. Included among the corrections are a completed description of an analytical methodology, additional discussion concerning the cost/benefit analysis and revised figures describing the extent of monitoring required.

FOR FURTHER INFORMATION CONTACT:
Joseph A. Cotruvo, Director, Criteria and
Standards Division, Office of Drinking
Water (WH-550), Environmental
Protection Agency, 401 M Street, S.W.,
Washington, D.C. 20460 (202-472-5016).
SUPPLEMENTARY INFORMATION: In
Federal Register Doc. 79-36442,
appearing at page 68624 in the Federal
Register of November 29, 1979, the


following changes should be made:

1. Page 68633—The existing Figure 1
should be replaced by the accompanying
Figure 1. "Considerations for Reduced
Monitoring Requirements, Surface
Water Systems."

U.S. Environment of the coverage

## FIGURE 1 CONSIDERATIONS FOR REDUCED MONITORING REQUIREMENTS SURFACE WATER SYSTEMS

THE MINIMUM MONITORING REQUIREMENT IS FOUR SAMPLES PER QUARTER PER PLANT. REDUCED MONITORING REQUIREMENTS MAY
BE APPROPRIATE IN CERTAIN CASES UPON WRITTEN REQUEST FROM
THE PUBLIC WATER SYSTEM STATES MAY REDUCE THE REQUIREMENTS THROUGH CONSIDERATION OF APPROPRIATE DATA AS FOLLOWS:



- \*FACTORS FOR CONSIDERATION:

   MUNITORING DATA, MTP, TTHM, TOC


   QUALITY AND STABILITY OF SOURCE WATER

   TYPE OF TREATMENT
- 2. Page 68635—The existing Figure 2 should be replaced by the accompanying Figure 2, "Considerations for Reduced

Monitoring Requirements, Groundwater

## FIGURE 2 CONSIDERATIONS FOR REDUCED MONITORING REQUIREMENTS **GROUNDWATER SYSTEMS**

THE MINIMUM MONITORING REQUIREMENT IS FOUR SAMPLES PER QUARTER PER PLANT; SYSTEMS USING MULTIPLE WELLS DRAWING RAW WATER FROM A SINGLE AQUIFER MAY WITH STATE APPROVAL BE CONSIDERED AS ONE TREATMENT PLANT. REDUCED MONITORING REQUIREMENTS MAY BE APPROPRIATE IN CERTAIN CASES; UPON WRITTEN REQUEST FROM THE PUBLIC WATER SYSTEM, STATES MAY REDUCE THE REQUIREMENTS THROUGH CONSIDERATION OF APPROPRIATE **DATA AS FOLLOWS:** 



- **\*FACTORS FOR CONSIDERATION:** 

  - MONITORING DATA, MTP, TTHM, TOC QUALITY AND STABILITY OF SOURCE WATER
  - **TYPE OF TREATMENT**

- 3. Page 68642—§ 141.30(e) should be revised in the eighth line of the second paragraph such that the words, "(or above)," are inserted immediately following the words, "25° C," and immediately preceeding the words, "prior to analysis."
- 4. Page 68642—§ 141.30(e)(1) should be revised such that the title refers to "Drinking" water rather than "Finished"
- 5. Page 68642—§ 141.30(f)(5) should be deleted in its entirety and replaced with the following, "Consider inclusion in the plan of provisions to maintain an active disinfectant residual throughout the distribution system at all times during and after the modification."
- 6. Page 68657—In the first column, the eighth and ninth lines of the second paragraph of comment #45 should read exactly as follows, "associated with chlorite and chlorate which are produced from . . . ."

7. Page 68664—In the third column, the ninth line of sub-paragraph two under comment #68 should read exactly as follows, "another for metabolically—."

8. Page 68672—In the second column, immediately following "Appendix C—Analysis of Trihalomethanes" and before "Part 1: The Analysis . . .," insert the following: "[Mention of trade names, products or company names do not constitute an endorsement or recommendation by the EPA.]"

9. Page 68672—In Part 1 of Appendix C, the numbering of the paragraphs in Section 2 should be revised as follows: Section 2.2 should be 2.1, Section 2.3 should be 2.2, Section 2.4 should be 2.3 and Section 2.5 should be 2.4.

10. Page 68674—Part 1 of Appendix C should be revised to reflect the fact that Sections 4.3 through 5.7, inclusive, were omitted. The omitted sections, which should be inserted accordingly, are as follows:

4.3 Sampling containers—40 ml screw cap vials sealed with Teflon faced silicone septa. Vials and caps—Pierce #13075 or equivalent. Septa—Pierce #12722 or equivalent.

4.4 Syringes—5-ml glass hypodermic with luerlok tip (2 each).

4.5 Micro syringes—10, 100 ul.
4.6 Micro syringe—25 ul with a 2" x
0.006" ID needle—Hamilton #702N, or
equivalent.

4.7 2-way syringe valve with luer ends (3 each) Hamilton #86570-1FM1, or equivalent.

4.8 Standard storage containers—15 ml amber screw-cap septum bottles with Teflon faced silicone septa. Bottles and Caps—Pierce #19830, or equivalent. Septa—Pierce #12716, or equivalent.

5. Reagents and Materials.

- 5.1 Porous polymer packing 60/80 mesh chromatographic grade Tenax GC (2.6-diphenylene oxide).
- 5.2 Three percent OV-1 Chromosorb-W 60/80 mesh.
- 5.3 1.0% SP-1000 on Carbopack-B (60/80 mesh) available from Supelco.
- 5.4 n-Octane on Porasil-C (100/120 mesh) available from Waters Associates.
- 5.5 Three percent SP-1000 on Chromosorb-W (60/80 mesh).
- 5.6 Free and combined chlorine reducing agent—crystalline sodium thiosulfate, ACS Reagent Grade or sodium sulfite, ACS Reagent Grade.
- 5.7 Activated carbon—Filtrasorb-200, available from Calgon Corporation, Pittsburgh, PA, or equivalent.
- 11. Page 68674—In the first column, change Section 5.9.3 to read exactly as follows: "Chlorodibromomethane—available from Columbia Organic Chemicals Company, Inc., 912 Drake Street, Box 9096 E, Columbia, SC, 29208 or Aldrich Chemical Company."

12. Page 68676—In the first column, change the last sentence in the narrative portion of Section 10.2 to read exactly as follows. "Round off the data to two significant figures."

13. Page 68676—In Table 1, revise the column entitled, "Acceptable Alternate to Column 1, 0.4% Carbowax Carbopack," as follows—change 0.4% to 0.2%.

14. Page 68684—In the first column, change Section 5.5.3 to read exactly as follows, "Chlorodibromomethane—available from Columbia Organic Chemicals Company, Inc., 912 Drake Street, Box 9096 E, Columbia, SC, 29208 or Aldrich Chemical Company."

15. Page 68688—In the first column, change the last sentence of the narrative portion of Section 9.2 to read exactly as follows, "Round off the data to two significant figures."

16. Page 68688—The upper right-hand corner of Figure 2 should be revised so that the title reads as follows:

"Column Packing: 10% Squalane, Carrier Flow: 25 ml/minute, Column Temperature: 67° C."

17. Page 68705—In the third column, the third reference (beginning with "Bellar, R. A.") should be revised to read exactly as follows, "Bellar, T. A., J. J. Lichienburg and R. C. Kroner. "The Occurrence of Organohalides in Chlorinated Drinking Waters." Journal of American Water Works Association 66: 12, 703-706, 1974."

18. Page 68704—In the third column, add the following discussion and table (that were prepared prior to the Administrator's signing of the

regulations but inadvertently omitted from the Statement of Basis and Purpose) to the end of Title IX, "Risk Assessment":

"As indicated by NAS, the value of avoiding a cancer death has been estimated to be from \$10,000 to \$1.3 million. An often used estimate is \$200,000, a figure based upon both cost earnings and social value. EPA feels that benefit-cost analysis using this methodology is more sophisticated than the available data. In response to the CWPS comments, the methodology was used to develop Figure 1. This figure shows the benefits associated with three MCL alternatives, associating a value of \$200,000 per case using the best estimate of 322 cases avoided. The cost of the regulation alternatives, as discussed in the economic impact assessment, are also shown. The largest vertical distance between the benefit and cost curves represents the maximum net benefit. At this point, the greatest economic efficiency is achieved. This point corresponds to an MCL of 0.105 mg/1. This figure suggests that an MCL of 0.100 mg/1 is clearly more economically efficient than other MCLs considered, based upon the most appropriate benefit and cost assumptions available.

19. Page 68706—In the third column, change the fourteenth reference [beginning with "Roe, F.J.C."] to read exactly as follows, "Roe, F.J.C., 'Preliminary Report of Long-Term Tests of Chloroform in Rats, Mice and Dogs.' Huntingdon Research Centre, Huntingdon, England, 1976."

U.S. En de mouden factuation Against Nagion 9, and strong Strong 233 South Chicago, Minetal 60004



